ArticleNature medicine2009
Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production.
Article in Nature medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 3 registered trials, which are not on this map. Cited by 1,232 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell (hMSC) Infusion in Patients With Non-Cystic Fibrosis Bronchiectasis
A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Mild Asthma
Clinical Study on Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Sepsis
Who cites it
1,232 citing papers in PubMed, 1 synthesis or guideline pooled it, 2,331 citations in OpenAlex.
- Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stromal Cell Therapy in Preclinical Models of Sepsis: A Systematic Review and Meta-analysis.Stem cells translational medicine · 2024Pooled it
- Multiroute administration of Wharton's jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study.World journal of stem cells · 2025Trial
- Trial
- Gut microbiota in chronic inflammation: the interplay with lipid mediators.Gut microbes · 2026Review
- Advances in 3D bioprinting of immunoregulatory biomaterials for bone regeneration.Materials today. Bio · 2026Review
- Cord-Derived Stem Cells for Pediatric Autism Spectrum Disorder: Biological Rationale and Source-Specific Trial Design.International journal of molecular sciences · 2026Review
- Promises and Perspectives of Mesenchymal Stromal Cells in Companion and Farm Animals.International journal of molecular sciences · 2026Review
- Enhanced odontoblast regeneration and anti-inflammatory effects of nanocurcumin-loaded BM-MSC-derived exosomes in an LPS-induced periodontitis rat model.BMC oral health · 2026Article
- Macrophage-driven pathological ossification of the posterior longitudinal ligament: mechanistic insights and therapeutic opportunities.Bone research · 2026Review
- Review
- Human iPSC-derived mesenchymal progenitor cell sheets promote tissue formation after xenotransplantation.iScience · 2026Article
- The importance of B cells for osteogenic homeostasis.Cell communication and signaling : CCS · 2026Article
- Mesenchymal Stromal Cell-Based Therapies in Sepsis-Induced Acute Lung and Kidney Injury: Current Advances and Perspectives.International journal of molecular sciences · 2026Review
- Cyclooxygenase-mediated IL-10Rα signaling underlies pro-tumor phenotypes of macrophages in glioma.Cell death & disease · 2026Article
- Cell pellets promote periodontal bone regeneration in furcation involvement by regulating macrophage polarization through TGF-β1 secretion.BMC oral health · 2026Article
- Mesenchymal Stem Cell-Based Therapy for Cerebellar Ataxia: From Bench to Bedside.CNS neuroscience & therapeutics · 2026Review
- Interleukin-10-engineered mesenchymal stem/stromal cells exhibit robust immunomodulatory effects in vitro and in vivo.Stem cell research & therapy · 2026Article
- Soluble PD-L1-secreting umbilical cord-derived mesenchymal stromal cells transiently attenuate established xenogeneic T cell activation in vivo.Scientific reports · 2026Article
- Clinical Development Programme of the Innovative Mesenchymal Stromal Cell Product MSC-FFM/MC0518 for Steroid-Refractory Acute Graft-Versus-Host Disease: Design of 2 Randomised Controlled Trials in Adult and Paediatric Patients.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Article
- Reciprocal Macrophage-MSC Crosstalk Drives Immunomodulatory and Regenerative Phenotypes in a Mineralized Collagen Scaffold.Journal of biomedical materials research. Part A · 2026Article
1,172 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
Abstract
Sepsis causes over 200,000 deaths yearly in the US; better treatments are urgently needed. Administering bone marrow stromal cells (BMSCs -- also known as mesenchymal stem cells) to mice before or shortly after inducing sepsis by cecal ligation and puncture reduced mortality and improved organ function. The beneficial effect of BMSCs was eliminated by macrophage depletion or pretreatment with antibodies specific for interleukin-10 (IL-10) or IL-10 receptor. Monocytes and/or macrophages from septic lungs made more IL-10 when prepared from mice treated with BMSCs versus untreated mice. Lipopolysaccharide (LPS)-stimulated macrophages produced more IL-10 when cultured with BMSCs, but this effect was eliminated if the BMSCs lacked the genes encoding Toll-like receptor 4, myeloid differentiation primary response gene-88, tumor necrosis factor (TNF) receptor-1a or cyclooxygenase-2. Our results suggest that BMSCs (activated by LPS or TNF-alpha) reprogram macrophages by releasing prostaglandin E(2) that acts on the macrophages through the prostaglandin EP2 and EP4 receptors. Because BMSCs have been successfully given to humans and can easily be cultured and might be used without human leukocyte antigen matching, we suggest that cultured, banked human BMSCs may be effective in treating sepsis in high-risk patient groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.